The hydrogen/deuterium-exchange (H/D-Ex) phenomenon is well established as a method for measuring binding interactions between a drug target and a ligand. ExSAR Corp. has developed an automated, rapid, and sensitive H/D-Ex system to rapidly map drug-target interactions in solution, for use in small-molecule drug discovery and also to assist in the stabilization and design of new protein therapeutics.
11 Deer Park Dr., Suite 103
Monmouth Junction, NJ 08852
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.
Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.
CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.
Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.
Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.
A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.
Insights from Novotech on Evolving Trends Impacting Global Clinical Development
